You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Article metrics

Article menu

Download PDFPDF

XML
Short Report
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 2019221
Jan 202013133
Feb 2020434311
Mar 2020515117
Apr 202044447
May 2020606011
Jun 202035357
Jul 2020232317
Aug 2020343426
Sep 2020919137
Oct 2020898735
Nov 2020767535
Dec 2020555527
Jan 2021606030
Feb 202110310341
Mar 2021777758
Apr 2021757537
May 202110110187
Jun 2021848461
Jul 2021666658
Aug 2021636357
Sep 202112512660
Oct 2021909157
Nov 2021787967
Dec 2021868755
Jan 20229610440
Feb 2022697646
Mar 2022828555
Apr 2022919358
May 202213714766
Jun 2022758346
Jul 2022717833
Aug 2022889241
Sep 2022707544
Oct 2022768142
Nov 202212012865
Dec 2022959542
Jan 202310210237
Feb 202310110350
Mar 202311411630
Apr 2023838545
May 202310911048
Jun 2023848523
Jul 2023646625
Aug 2023687337
Sep 2023838622
Oct 202319319642
Nov 202334334433
Dec 202311011152
Jan 202419519839
Feb 202412212943
Mar 202410110365
Total456646692071